Description
Wiseguyreports.Com Adds “Antiulcerant Drugs -Market Demand, Growth, Opportunities and Analysis Of Top Key Player Forecast To 2024” To Its Research Database
The global antiulcerant drugs market growth outlook is positive with significant growth potential for antiulcerant drugs market in emerging countries. Rising disposable income in developed countries, growing awareness of the disease, busy lifestyles, technological advances such as big data, 3D printing and IoT is aiding the antiulcerant drugs market growth.
The market for antiulcerant drugs reached a value of nearly $REDACTED billion in 2017 and is expected togrow at a compound annual growth rate (CAGR) of REDACTED% to nearly $REDACTED billion by 2020. The market for antiulcerant drugs is fragmented with a large number of players. Major players in the market are AstraZeneca PLC, Allergan plc, Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd ,Takeda Pharmaceutical Company others. Proton Pump Inhibitors accounted for the largest share of the market for antiulcerant drugs market in 2017 at REDACTED%. The highest growth is projected to come from H2 Receptor Antagonists segment which is forecasted to grow at a CAGR of REDACTED%. Major factors
includedageing population, sedentary lifestyles and increasing awareness on ulcer disease.
North America is the largest market for antiulcerant drugs market, accounting for REDACTED% of the globalmarket. It was followed by Asia Pacific and Western Europe. Going forward, Africa is expected to witnessthe fastest growth in the antiulcerant drugs market, estimated at grow at a CAGR of REDACTED%, followed byNorth America, which is expected to grow at a CAGR of REDACTED%.
Request for Sample Report @ https://www.wiseguyreports.com/sample-request/3195995-antiulcerant-drugs-global-markets-to-2022
The USA is the largest market in terms of value and in the antiulcerant drugs market. India and china are forecasted to have the fastest growth, growing at a CAGR of REDACTED% and REDACTED%, respectively. The market is challenged by restraints such as unfavorable laws for drug patents and rising trade protectionism.
Report Scope:
This research report categorizes the antiulcerant drugs market by type, including proton pump inhibitors, H2 receptor antagonists, gastric mucosal protective drugs, antibiotics, antacids and prostaglandin agonists.
Report Includes:
– 97 data tables
– Country specific data and analysis for China, India, Japan, Australia, UK, Germany, France, Italy, Spain, Russia, USA and Brazil
– Insight into technological advances, such as big data, 3D printing and IoT in the growth of the antiulcerants drugs market
– Coverage of definition, types, causes, and treatment options for ulcers
– Description of the modes of action of various antiulcer drugs
– Comprehensive profiles of major players in the market, including AstraZeneca, Allergan, Daewoong Pharmaceutical, Eisai, and Takeda PharmaceuticalALLERGAN PLC.
ASTRAZENECA PLC
DAEWOONG PHARMACEUTICAL CO., LTD.
EISAI CO., LTD.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Table of Contents
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Antiulcerant Drugs Market Overview
Chapter 4 PESTEL Analysis
Chapter 5 Global Antiulcerant Drugs Market Comparison with Macro Economic Factors
Chapter 6 Antiulcerant Drugs Market Segmentation
Chapter 7 Antiulcerant Drugs Market Regional and Country Analysis
Chapter 8 Asia-Pacific Antiulcerant Drugs Market
Chapter 9 Western Europe Antiulcerant Drugs Market
Chapter 10 Eastern Europe Antiulcerant Drugs Market
Chapter 11 North America Antiulcerant Drugs Market
Chapter 12 South America Antiulcerant Drugs Market
Chapter 13 Middle East Antiulcerant Drugs Market
Chapter 14 Africa Antiulcerant Drugs Market
Chapter 15 Antiulcerant Drugs Market Competitive Landscape
Company Profiles
ALLERGAN PLC.
ASTRAZENECA PLC
DAEWOONG PHARMACEUTICAL CO., LTD.
EISAI CO., LTD.
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Chapter 16 Key Mergers and Acquisitions in the Antiulcerant drugs Market
Valeant Acquired Salix Pharmaceuticals
Shire Acquired Meritage Pharma
Zydus Acquired Albert David
Allergan Acquired AstraZeneca’s IBD Drug
Chapter 17 Appendix
Chapter 18 References
Leave a Query @ https://www.wiseguyreports.com/enquiry/3195995-antiulcerant-drugs-global-markets-to-2022
Continued…
Contact Us: Sales@Wiseguyreports.Com Ph: +1-646-845-9349 (Us) Ph: +44 208 133 9349 (Uk)
Your information will never be shared with any third party.